Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 2021;184:5309–37. https://doi.org/10.1016/j.cell.2021.09.020.

Article  CAS  PubMed  Google Scholar 

Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res 2021;27:4685–9. https://doi.org/10.1158/1078-0432.CCR-21-0327.

Article  CAS  PubMed  Google Scholar 

Haddad RI. NCCN Guidelines Version 4.2024 Thyroid Carcinoma. n.d.

Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 2019;4:e126908, 126908. https://doi.org/10.1172/jci.insight.126908.

Article  PubMed  Google Scholar 

Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 2022;20:925–51. https://doi.org/10.6004/jnccn.2022.0040.

Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunotherapy Cancer 2018;6:68. https://doi.org/10.1186/s40425-018-0378-y.

Article  Google Scholar 

Naing A, Gainor JF, Gelderblom H, Forde PM, Butler MO, Lin C-C, et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer 2020;8:e000530. https://doi.org/10.1136/jitc-2020-000530.

Article  PubMed  Google Scholar 

Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin C-C, Ramlau R, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol 2020;38:2620–7. https://doi.org/10.1200/JCO.19.02727.

Article  CAS  PubMed  Google Scholar 

Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid 2021;31:1076–85. https://doi.org/10.1089/thy.2020.0322.

Article  CAS  PubMed  Google Scholar 

Lee NY, Riaz N, Wu V, Brinkman T, Tsai CJ, Zhi W, et al. A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. Thyroid 2022;32:799–806. https://doi.org/10.1089/thy.2022.0050.

Article  CAS  PubMed  Google Scholar 

Hatashima A, Archambeau B, Armbruster H, Xu M, Shah M, Konda B, et al. An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma. Thyroid 2022;32:926–36. https://doi.org/10.1089/thy.2022.0073.

Article  CAS  PubMed  Google Scholar 

Pusztaszeri MP, Bongiovanni M, Brimo F. Do we need PD-L1 as a biomarker for thyroid cytologic and histologic specimens? Cancer Cytopathol 2020;128:160–5. https://doi.org/10.1002/cncy.22223.

Article  PubMed  Google Scholar 

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018;24:541–50. https://doi.org/10.1038/s41591-018-0014-x.

Article  CAS  PubMed  Google Scholar 

Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Sig Transduct Target Ther 2021;6:72. https://doi.org/10.1038/s41392-020-00449-4.

Article  Google Scholar 

Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Sci Transl Med 2012;4. https://doi.org/10.1126/scitranslmed.3003689.

Sun D, Liu J, Zhou H, Shi M, Sun J, Zhao S, et al. Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC. Journal of Thoracic Oncology 2023;18:869–81. https://doi.org/10.1016/j.jtho.2023.03.012.

Article  CAS  PubMed  Google Scholar 

Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discov 2022;21:529–40. https://doi.org/10.1038/s41573-022-00493-5.

Article  CAS  PubMed  Google Scholar 

Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology 2021;53:141–56. https://doi.org/10.1016/j.pathol.2020.10.007.

Article  CAS  PubMed  Google Scholar 

Cheung CC, Barnes P, Bigras G, Boerner S, Butany J, Calabrese F, et al. Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). Applied Immunohistochemistry & Molecular Morphology 2019;27:699–714. https://doi.org/10.1097/PAI.0000000000000800.

Article  Google Scholar 

Agarwal S, Jung CK, Gaddam P, Hirokawa M, Higashiyama T, Hang J-F, et al. PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma: A Multi-institutional Study. Am J Surg Pathol 2024. https://doi.org/10.1097/PAS.0000000000002284.

Article  PubMed  Google Scholar 

Ishii H, Azuma K, Kawahara A, Matsuo N, Tokito T, Kinoshita T, et al. Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget 2017;8:61618–25. https://doi.org/10.18632/oncotarget.18651.

Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. Journal of Experimental Medicine 2010;207:2187–94. https://doi.org/10.1084/jem.20100643.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Curley J, Conaway MR, Chinn Z, Duska L, Stoler M, Mills AM. Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia. Modern Pathology 2020;33:1182–92. https://doi.org/10.1038/s41379-019-0433-3.

Article  CAS  PubMed  Google Scholar 

McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716–21.

Boruah M, Gaddam P, Agarwal S, Mir RA, Gupta R, Sharma MC, et al. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy. J Cancer Res Ther 2023;19:312–20. https://doi.org/10.4103/jcrt.jcrt_1471_22.

Article  CAS  PubMed  Google Scholar 

Giannini R, Moretti S, Ugolini C, Macerola E, Menicali E, Nucci N, et al. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like. The Journal of Clinical Endocrinology & Metabolism 2019. https://doi.org/10.1210/jc.2018-01167.

Article  Google Scholar 

Feng C, Tao Y, Yu C, Wang L, Liu X, Cao Y. Integrative single-cell transcriptome analysis reveals immune suppressive landscape in the anaplastic thyroid cancer. Cancer Gene Ther 2023. https://doi.org/10.1038/s41417-023-00663-6.

Article  PubMed  Google Scholar 

Ryder M, Ghossein RA, Ricarte-Filho JCM, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocrine Related Cancer 2008;15:1069–74. https://doi.org/10.1677/ERC-08-0036.

Article  CAS  PubMed  Google Scholar 

Luo Y, Yang Y-C, Ma B, Xu W-B, Liao T, Wang Y. Integrated analysis of novel macrophage related signature in anaplastic thyroid cancer. Endocrine 2022;78:517–30. https://doi.org/10.1007/s12020-022-03179-5.

Article  CAS  PubMed  Google Scholar 

Ugolini C, Basolo F, Proietti A, Vitti P, Elisei R, Miccoli P, et al. Lymphocyte and Immature Dendritic Cell Infiltrates in Differentiated, Poorly Differentiated, and Undifferentiated Thyroid Carcinoma. Thyroid 2007;17:389–93. https://doi.org/10.1089/thy.2006.0306.

Article  PubMed  Google Scholar 

Jung KY, Cho SW, Kim YA, Kim D, Oh B-C, Park DJ, et al. Cancers with Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates. J Pathol Transl Med 2015;49:318–24. https://doi.org/10.4132/jptm.2015.06.01.

Article  PubMed  Google Scholar 

Wang X, Peng W, Li C, Qin R, Zhong Z, Sun C. Identification of an immune-related signature indicating the dedifferentiation of thyroid cells. Cancer Cell Int 2021;21:231. https://doi.org/10.1186/s12935-021-01939-3.

Article  CAS  PubMed  Google Scholar 

Ono T, Azuma K, Kawahara A, Sasada T, Matsuo N, Kakuma T, et al. Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment. Head & Neck 2018;40:2007–19. https://doi.org/10.1002/hed.25189.